Tailoring of FcRn-Targeted Molecules for Favorable Binding and Transport Properties
Jan Terje Andersen, Professor, Department of Pharmacology, University of Oslo; Research Group Leader, Department of Immunology, Oslo University Hospital
Antibody-Cytokine Fusions: Emerging Clinical Data in Glioblastoma, Sarcoma, and Dermato-Oncology Indications
Dario Neri, PhD, CEO and CSO, Philogen
Stage-Specific Analytical Development for AAV Gene Therapy Vectors
Liz Higgins, PhD, Vice President, Head of CMC, NysnoBio
Design and Engineering of Mammalian Cell Expression Systems Using Synthetic Biology
David C. James, PhD, Professor, Bioprocess Engineering, University of Sheffield
Development of New Stimuli-Sensitive Antibodies
Benjami Oller-Salvia, PhD, Assistant Professor, "La Caixa" Junior Leader Fellow, Bioengineering, Protein and Peptide Targeted Nanotherapeutics Program, Ramon Llull University
The End of One Era and the Beginning of a New One: The State of Cancer Immunotherapy and Opportunities for Next-Generation Engineered Therapeutics
Daniel Chen, MD, PhD, Founder, Engenuity Life Sciences
Advances in Bispecific T Cell Engager Therapies
Bahija Jallal, PhD, CEO, Immunocore LLC
Building Analytical Platform to Enable Efficient Drug Development
Bernice Yeung, PhD, Head of Analytical Development (Chemistry), Biogen
Applications of Machine Learning and Informatics in Antibody Discovery
Charlotte M. Deane, PhD, Professor of Structural Bioinformatics, Statistics, University of Oxford
Nanobodies Modulating Human and Viral Chemokine Receptor Function
Martine Smit, PhD, Professor Target and Systems Biochemistry, Vrije Universiteit Amsterdam
Ten Years in the Making – Therapeutic Applications of CrossMab Technology
Christian Klein, PhD, Cancer Immunotherapy Discovery, Roche Innovation Center Zurich, Roche Pharma Research & Early Development, pRED
Trispecific Antibodies – Taking the Concept of Multi-Targeting One Step Further
Ercole Rao, PhD, Group Leader Biologics Research, Engineered Protein Therapeutics, Sanofi Germany GmbH
Overcoming Safety and Efficacy Challenges of Dual Checkpoint Inhibitor Combinations
Jonathan D. Cheng, Senior Vice President & Therapeutic Area Head, Oncology Clinical Development, Bristol Myers Squibb Co.
A Structure-Based Approach to Tackle Protein Aggregation in Parkinson's Disease
Salvador Ventura, PhD, Professor & Chair, Biochemistry & Molecular Biology, University Autonoma De Barcelona
Why you Need Both Crystallography and EM to Study GPCRs and Design Drugs, and How to Get There
Andreas G. Plueckthun, PhD, Professor & Head, Biochemistry, University of Zurich